Related Experiment Videos
Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT)
1Divisione Ematologia II Ospedale San Martino, Genova, Italy.
Bone Marrow Transplantation
|February 23, 2002
Summary
Reduced intensity allogeneic stem cell transplants (RI-HSCT) show similar transplant-related mortality (TRM) across different conditioning regimens. Graft-versus-host disease (GVHD) risks may vary, with higher rates in older patients and those with solid tumors.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Reduced intensity allogeneic stem cell transplantation (RI-HSCT) is increasingly explored for older patients and those with solid tumors.
- A 2001 Zurich meeting convened experts to analyze transplant-related mortality (TRM) and graft-versus-host disease (GVHD) in RI-HSCT.
Framework:
- Analysis of retrospective and prospective studies involving over 900 patients from EBMT, national, and single institutions.
- Classification of conditioning regimens into four main groups based on TBI, busulfan, thiotepa, or melphalan, often combined with fludarabine.
- Utilized mobilized peripheral blood as the stem cell source.
Implementation:
- Acute GVHD (grade III-IV) incidence was 12% (1-17%).
- Extensive chronic GVHD occurred in 42% (25-51%) of patients.
- TRM incidence was 20% (14-38%), with similar rates across the four conditioning regimens.
Implications:
- RI-HSCT is feasible in elderly patients, with an expected TRM of approximately 15%, which is age-dependent.
- High rates of extensive chronic GVHD necessitate careful monitoring.
- The term 'mini-transplant' is discouraged; 'allogeneic HSCT' with conditioning intensity classification is preferred.